5-Hydroxytryptamine 2A receptor signaling cascade modulates adiponectin and plasminogen activator inhibitor 1 expression in adipose tissue

FEBS Letters

Volumn 582, Issue 20, 2008, Pages 3037-3044

  Uchida Kitajima, Shoko ^a,b   Yamauchi, Toshimasa ^b,c   Takashina, Youko ^a   Okada Iwabu, Miki ^b,c   Iwabu, Masato ^b,c   Ueki, Kohjiro ^b   Kadowaki, Takashi ^b,c  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 HT2A receptor; Adipocytes; Adiponectin; Plasminogen activator inhibitor 1; Sarpogrelate

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE TRANSPORT; HYPERTROPHY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, SEROTONIN, 5-HT2A; SIGNAL TRANSDUCTION;

EID: 49649105198     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.07.044     Document Type: Article

References (31)

1. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860-867
2. Reaven G.M. The fourth musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 38 (1995) 3-13
3. Spiegelman B.M., and Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87 (1996) 377-389
4. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
5. Yamauchi T., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276 (2001) 41245-41254
6. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
7. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7 (2001) 947-953
8. Kubota N., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277 (2002) 25863-25866
9. Yamauchi T., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
10. Yamauchi T., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278 (2003) 2461-2468
11. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
12. Kubota N., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 (1999) 597-609
13. Arita Y., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
14. Kadowaki T., et al. The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. J. Diabetes Complications 16 (2002) 41-45
15. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. New Engl. J. Med. 342 (2000) 1792-1801
16. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., and Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 41 (1998) 65-71
17. Maruyama K., Kinami J., Sugita Y., Takada Y., Sugiyama E., Tsuchihashi H., and Nagatomo T. MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. J. Pharmacobiodyn. 14 (1991) 177-181
18. Yamakawa J., Takahashi T., Itoh T., Kusaka K., Kawaura K., Wang X.Q., and Kanda T. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 26 (2003) 2477-2478
19. Nomura S., Shouzu A., Omoto S., Nishikawa M., and Iwasaka T. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Blood Coagul. Fibrinolysis 16 (2005) 423-428
20. Kokubu N., et al. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ. J. 70 (2006) 1451-1456
21. Cerrito F., Lazzaro M.P., Gaudio E., Arminio P., and Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci. 53 (1993) 209-215
22. Kawano H., et al. Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97 (2001) 1697-1702
23. Rosen E.D., Walkey C.J., Puigserver P., and Spiegelman B.M. Transcriptional regulation of adipogenesis. Genes Dev. 14 (2000) 1293-1307
24. Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
25. Glennon R.A., Metwally K., Dukat M., Ismaiel A.M., De los Angeles J., Herndon J., Teitler M., and Khorana N. Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists. Curr. Top. Med. Chem. 2 (2002) 539-558
26. Shum J.K., Melendez J.A., and Jeffrey J.J. Serotonin-induced MMP-13 production is mediated via phospholipase C, protein kinase C, and ERK1/2 in rat uterine smooth muscle cells. J. Biol. Chem. 277 (2002) 42830-42840
27. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
28. Hu E., Kim J.B., Sarraf P., and Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274 (1996) 2100-2103
29. Welsh D.J., Harnett M., MacLean M., and Peacock A.J. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am. J. Respir. Crit. Care Med. 170 (2004) 252-259
30. Nerurkar S.S., et al. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomarkers 12 (2007) 87-112
31. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517